Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1066 AL 1080

Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer's Disease and Down Syndrome

Meijer L, Chrétien E, Ravel D.

J Alzheimers Dis. 2024;101(s1):S95-S113. doi: 10.3233/JAD-240078.

Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment

Lim AWY, Schneider L, Loy C.

Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4.

Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophrenia, Agitation in Alzheimer's Disease, and Posttraumatic Stress Disorder

Jain R, Chepke C, Davis LL, McIntyre RS, Raskind MA.

J Clin Psychiatry. 2024 Nov 8;85(4):plunaro2417ah. doi: 10.4088/JCP.plunaro2417ah.

Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease: A 12-week, active-treatment, extension trial

Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, Shah A, Estilo A, Kalu U, Hobart M.

J Alzheimers Dis. 2024 Nov;102(2):520-529. doi: 10.3233/JAD-240491. Epub 2024 Nov 13.

Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center

Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, Freeman SW, Cain JF, Shang WY, Wasz KM, Orr AT, Shields CB, Barve SS, Pugh KG.

J Prev Alzheimers Dis. 2024;11(6):1549-1562. doi: 10.14283/jpad.2024.159.

Effect of Social Isolation Due to the COVID-19 Pandemic on Cognitive Dysfunction of Patients With Alzheimer Disease: Subanalysis of Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets

Nakamura Y, Omori T, Nishiyama K, Ishikawa I, Aoki H, Nagakura N.

Alzheimer Dis Assoc Disord. 2024 Oct-Dec 01;38(4):351-357. doi: 10.1097/WAD.0000000000000648. Epub 2024 Nov 13.

The Role of Non-coding RNAs in Alzheimer's Disease: Pathogenesis, Novel Biomarkers, and Potential Therapeutic Targets

Saleh O, Albakri K, Altiti A, Abutair I, Shalan S, Mohd OB, Negida A, Mushtaq G, Kamal MA.

CNS Neurol Disord Drug Targets. 2024;23(6):731-745. doi: 10.2174/1871527322666230519113201.

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial

Brum WS, Docherty KF, Ashton NJ, Zetterberg H, Hansson O, McMurray JJV, Blennow K.

JAMA Neurol. 2024 Feb 1;81(2):197-200. doi: 10.1001/jamaneurol.2023.4719.

Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease

Weinberg MS, He Y, Kivisäkk P, Arnold SE, Das S.

J Alzheimers Dis. 2024;99(s2):S355-S365. doi: 10.3233/JAD-230899.

Navigating the dementia landscape: Biomarkers and emerging therapies

Maheshwari S, Singh A, Ansari VA, Mahmood T, Wasim R, Akhtar J, Verma A.

Ageing Res Rev. 2024 Feb;94:102193. doi: 10.1016/j.arr.2024.102193. Epub 2024 Jan 10.

Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives

Lista S, Santos-Lozano A, Emanuele E, Mercuri NB, Gabelle A, López-Ortiz S, Martín-Hernández J, Maisto N, Imbimbo C, Caraci F, Imbimbo BP, Zetterberg H, Nisticò R.

Mol Psychiatry. 2024 Mar;29(3):847-857. doi: 10.1038/s41380-023-02376-6. Epub 2024 Jan 16.

Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease

Cantillon M, Andreasen N, Prins N.

J Prev Alzheimers Dis. 2024;11(1):65-70. doi: 10.14283/jpad.2024.2.

Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia

McInvale JJ, Canoll P, Hargus G.

Brain Pathol. 2024 Jul;34(4):e13231. doi: 10.1111/bpa.13231. Epub 2024 Jan 21.

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis

Chapleau M, La Joie R, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Filippi M, Fumagalli GG, Galimberti D, Graff-Radford J, Grinberg LT, Irwin DJ, Josephs KA, Mendez MF, Mendez PC, Migliaccio R, Miller ZA, Montembeault M, Murray ME, Nemes S, Pelak V, Perani D, Phillips J, Pijnenburg Y, Rogalski E, Schott JM, Seeley W, Sullivan AC, Spina S, Tanner J, Walker J, Whitwell JL, Wolk DA, Ossenkoppele R, Rabinovici GD; PCA International Work Group.

Lancet Neurol. 2024 Feb;23(2):168-177. doi: 10.1016/S1474-4422(23)00414-3.

A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease

van Dyck CH, Mecca AP, O'Dell RS, Bartlett HH, Diepenbrock NG, Huang Y, Hamby ME, Grundman M, Catalano SM, Caggiano AO, Carson RE.

Alzheimers Res Ther. 2024 Jan 25;16(1):20. doi: 10.1186/s13195-024-01382-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias